You just read:

Merck KGaA, Darmstadt, Germany and GSK Announce Global Alliance to Jointly Develop and Commercialize M7824, a Novel Immunotherapy with Potential in Multiple Difficult-to-Treat Cancers

News provided by

Merck KGaA

Feb 05, 2019, 07:21 ET